1y return+87.0%S&P 500 +20.9%
3y return+79.3%S&P 500 +68.5%
5y return+35.5%S&P 500 +74.5%
10y return+128.0%S&P 500 +256.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2016: $228 against $357 in the S&P 500.2
Sectoral Asset Management IncS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CTNMContineum Therapeutics | $11.9M | 8.3% | |
| SIShoulder Innovations | $8.7M | 6.1% | |
| LLYEli Lilly & Co | $7.6M | 5.3% | |
| UNHUnitedhealth Grp Inc | $5.5M | 3.8% | −11.5% |
| JNJJohnson & Johnson | $4.6M | 3.2% | |
| ORKAOruka Therapeutics Inc | $4.0M | 2.8% | New |
| BNTXBiontech Se | $3.9M | 2.7% | +88.9% |
| DFTXDefinium Therapeutics Inc | $3.7M | 2.6% | New |
| DXCMDexcom Inc | $3.4M | 2.4% | +118.5% |
| RCUSArcus Biosciences | $3.4M | 2.4% | +146.0% |
| AMGNAmgen Inc | $3.3M | 2.3% | |
| SMMTSummit Therapeutics | $3.2M | 2.2% | +216.3% |
| IRTCIrhythm Holdings Inc | $3.1M | 2.2% | New |
| ABBVAbbvie Inc | $3.1M | 2.1% | |
| MRKMerck & Co Inc | $2.8M | 1.9% | |
| AVBPArrivent Biopharma | $2.7M | 1.9% | +163.4% |
| VRTXVertex Pharma | $2.7M | 1.9% | −22.5% |
| ARGXArgenx Se | $2.6M | 1.8% | −20.6% |
| GILDGilead Sciences Inc | $2.6M | 1.8% | −25.0% |
| INSMInsmed Inc | $2.5M | 1.7% | +18.0% |
| TECXTectonic Therapeutic | $2.4M | 1.7% | +272.6% |
| ISRGIntuitive Surgic Inc | $2.3M | 1.6% | +11.4% |
| Immatics NvCUSIP N44445109 | $2.3M | 1.6% | +236.6% |
| SYKStryker Corp | $2.2M | 1.6% | +21.4% |
| AVTXAvalo Therapeutics Inc | $2.2M | 1.5% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| SMMTSummit Therapeutics | March 31, 2023 | +732.6% | $3.2M |
| LLYEli Lilly & Co | June 30, 2020 | +630.6% | $7.6M |
| Roivant Sciences LtdCUSIP G76279101 | December 31, 2022 | +342.9% | $2.2M |
| INSMInsmed Inc | March 31, 2021 | +213.0% | $2.5M |
| TRVITrevi Therapeutics | March 31, 2025 | +196.5% | $1.2M |
| ABBVAbbvie Inc | June 30, 2020 | +156.3% | $3.1M |
| ARGXArgenx Se | June 30, 2022 | +144.9% | $2.6M |
| CYTKCytokinetics Inc | March 31, 2022 | +131.4% | $1.4M |
| Immatics NvCUSIP N44445109 | June 30, 2025 | +88.3% | $2.3M |
| AVBPArrivent Biopharma | March 31, 2025 | +87.9% | $2.7M |
Sold off last quarter
- EVMNEvommune Inc was $13.5M
- RAPPRapport Therapeutics was $835K
- BOLDBoundless Bio was $746K
- Ascendis Pharma A SCUSIP 04351P101 was $728K
- Uniqure N.v.CUSIP N90064101 was $499K
- ALHCAlignment Health was $474K
- RDNTRadnet Inc was $447K
- INSPInspire Med Sys Inc was $373K
- NBIXNeurocrine Biosciences was $344K
- OMDAOmada Health Inc was $322K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +6.8% | +14.8% |
| March 31, 2026 | −0.6% | −4.6% |
| December 31, 2025 | +25.6% | +2.4% |
| September 30, 2025 | +40.4% | +7.8% |
| June 30, 2025 | −2.7% | +10.5% |
| March 31, 2025 | −5.9% | −4.6% |
| December 31, 2024 | −6.2% | +2.1% |
| September 30, 2024 | +7.3% | +5.4% |
| June 30, 2024 | −2.9% | +4.0% |
| March 31, 2024 | +9.5% | +10.0% |
| December 31, 2023 | +13.4% | +11.2% |
| September 30, 2023 | −13.8% | −3.6% |
| June 30, 2023 | +9.9% | +8.3% |
| March 31, 2023 | −0.9% | +7.0% |
| December 31, 2022 | −1.1% | +7.1% |
| September 30, 2022 | +2.8% | −5.3% |
| June 30, 2022 | −9.8% | −16.5% |
| March 31, 2022 | −14.9% | −4.9% |
| December 31, 2021 | −6.1% | +10.7% |
| September 30, 2021 | −5.2% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Sectoral Asset Management Inc Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1274413&type=13F-HR&dateb=&owner=include&count=40CIK 1274413
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1274413/000110465926096554/Filed August 14, 2026 · accession 0001104659-26-096554